• Private Equity Firm

    Shavit Capital is an investment firm that specializes in late-stage investments in Israeli and Israeli-related companies.

    Shavit Capital has over $400 million under management across five separate private equity funds. Shavit Capital was founded in 2008 and the fifth fund was raised in 2019.  The Funds invest in Israeli companies with proven technologies, products, markets and strong management teams. The Funds invest in equity mezzanine or bridge rounds in companies which subsequently expect to raise relatively larger amounts pursuant to an IPO on a major international public exchange or a dual listing of a company that trades on the Tel Aviv Stock Exchange.

    Shavit Capital also invests in other late-stage opportunities, especially through PIPEs (Private Investment in Public Equites) of Israeli publicly-traded companies.

  • Company News

    Trax plans New York IPO at $2b valuation, Israel layoffs
    January 20, 2021
    Alpha Tau Medical Announces Appointment of Peter Melnyk as New Board Member
    January 12, 2021
    PolyPid Announces Positive Preclinical Data from OncoPLEX Intra-Tumoral Cance
    December 22, 2020
    Gamida Cell Announces Closing of $75 Million Public Offering, Including Full
    December 21, 2020
    Mapi Pharma Provides Enrollment Update in Phase III GA Depot Clinical Trial
    December 21, 2020
    PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX₁₀₀
    December 16, 2020
    Anchiano Therapeutics jumps after Chemomab merger
    December 15, 2020
    Revolutionary Israeli bone marrow transplant method meets trial goals
    December 12, 2020
    PolyPid Granted Breakthrough Therapy Designation from FDA for D-PLEX₁₀₀
    November 24, 2020
    Gamida Cell and Be The Match BioTherapies® Expand Strategic Collaboration
    October 13, 2020